[go: up one dir, main page]

FI20002127A0 - Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi - Google Patents

Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Info

Publication number
FI20002127A0
FI20002127A0 FI20002127A FI20002127A FI20002127A0 FI 20002127 A0 FI20002127 A0 FI 20002127A0 FI 20002127 A FI20002127 A FI 20002127A FI 20002127 A FI20002127 A FI 20002127A FI 20002127 A0 FI20002127 A0 FI 20002127A0
Authority
FI
Finland
Prior art keywords
pca
patients
psa
antibody
prostate
Prior art date
Application number
FI20002127A
Other languages
English (en)
Swedish (sv)
Inventor
Kim Pettersson
Timo Loevgren
Hans Lilja
Pauliina Nurmikko
Original Assignee
Artic Partners Oy Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artic Partners Oy Ab filed Critical Artic Partners Oy Ab
Priority to FI20002127A priority Critical patent/FI20002127A0/fi
Publication of FI20002127A0 publication Critical patent/FI20002127A0/fi
Priority to PCT/FI2001/000834 priority patent/WO2002027323A1/en
Priority to JP2002530851A priority patent/JP5254517B2/ja
Priority to EP01972118A priority patent/EP1320756B1/en
Priority to AU2001291911A priority patent/AU2001291911A1/en
Priority to DE60137949T priority patent/DE60137949D1/de
Priority to ES01972118T priority patent/ES2322432T3/es
Priority to US10/381,132 priority patent/US7872104B2/en
Priority to AT01972118T priority patent/ATE425460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G01N33/57555—

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI20002127A 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi FI20002127A0 (fi)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
PCT/FI2001/000834 WO2002027323A1 (en) 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection
JP2002530851A JP5254517B2 (ja) 2000-09-27 2001-09-26 新規抗体、イムノアッセイおよび前立腺癌検出方法
EP01972118A EP1320756B1 (en) 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection
AU2001291911A AU2001291911A1 (en) 2000-09-27 2001-09-26 Novel antibody, immunoassay and method for prostate cancer detection
DE60137949T DE60137949D1 (de) 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
ES01972118T ES2322432T3 (es) 2000-09-27 2001-09-26 Nuevo anticuerpo, inmunoensayo y procedimiento para la deteccion del cancer de protasta.
US10/381,132 US7872104B2 (en) 2000-09-27 2001-09-26 Antibody, immunoassay and method for prostate cancer detection
AT01972118T ATE425460T1 (de) 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Publications (1)

Publication Number Publication Date
FI20002127A0 true FI20002127A0 (fi) 2000-09-27

Family

ID=8559172

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Country Status (9)

Country Link
US (1) US7872104B2 (fi)
EP (1) EP1320756B1 (fi)
JP (1) JP5254517B2 (fi)
AT (1) ATE425460T1 (fi)
AU (1) AU2001291911A1 (fi)
DE (1) DE60137949D1 (fi)
ES (1) ES2322432T3 (fi)
FI (1) FI20002127A0 (fi)
WO (1) WO2002027323A1 (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754812B (zh) 2007-05-04 2013-06-26 克拉洛诊断仪器公司 流体连接器和微流体系统
US8221700B2 (en) 2009-02-02 2012-07-17 Opko Diagnostics, Llc Structures for controlling light interaction with microfluidic devices
WO2013063312A1 (en) * 2011-10-25 2013-05-02 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
PT2771037T (pt) 2011-10-28 2016-11-08 Fredax Ab Agentes terapêuticos e utilizações dos mesmos
EA030682B1 (ru) 2012-03-05 2018-09-28 Ой Арктик Партнерс Аб Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
JP6312141B2 (ja) * 2012-03-30 2018-04-18 国立大学法人京都大学 前立腺がん検査用尿中バイオマーカー
JP6599859B2 (ja) 2013-11-19 2019-10-30 フレダックス・アクチエボラーグ ヒト化抗カリクレイン−２抗体
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
JP6775488B2 (ja) * 2014-03-28 2020-10-28 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ 前立腺がんの診断に関連する組成物および方法
US11921115B2 (en) * 2015-03-27 2024-03-05 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
AU2016254127B2 (en) * 2015-04-29 2022-05-26 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3922265A1 (en) * 2015-10-05 2021-12-15 Fredax AB Humanized anti psa (5a10) antibodies
CN109991405B (zh) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 一种免疫检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635575A1 (en) * 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
JPH10150999A (ja) * 1996-11-22 1998-06-09 Eiken Chem Co Ltd ヒト前立腺特異抗原−α１−アンチキモトリプシン複合体に対するモノクローナル抗体及びそれを用いたヒト前立腺特異抗原−α１−アンチキモトリプシン複合体の免疫学的検出法
US5858685A (en) * 1997-03-21 1999-01-12 The Board Of Trustees Of The Leland Stanford Junior University Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
DE69839876D1 (de) * 1997-04-30 2008-09-25 Hybritech Inc Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
US7659073B2 (en) * 1997-04-30 2010-02-09 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone
US6482599B1 (en) * 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection

Also Published As

Publication number Publication date
EP1320756A1 (en) 2003-06-25
JP2004509934A (ja) 2004-04-02
US7872104B2 (en) 2011-01-18
ES2322432T3 (es) 2009-06-22
WO2002027323A1 (en) 2002-04-04
US20040101914A1 (en) 2004-05-27
AU2001291911A1 (en) 2002-04-08
EP1320756B1 (en) 2009-03-11
DE60137949D1 (de) 2009-04-23
JP5254517B2 (ja) 2013-08-07
ATE425460T1 (de) 2009-03-15

Similar Documents

Publication Publication Date Title
Mönig et al. Expression of MMP‐2 is associated with progression and lymph node metastasis of gastric carcinoma
Xing et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin
FI20002127A0 (fi) Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
Chan et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen
Tutton et al. Use of plasma MMP‐2 and MMP‐9 levels as a surrogate for tumour expression in colorectal cancer patients
Fritzsche et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
Chang et al. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen
Chenard et al. High levels of stromelysin‐3 correlate with poor prognosis in patients with breast carcinoma
Mikolajczyk et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia
Stephan et al. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer
Lilja et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
Cho et al. High level of urokinase‐type plasminogen activator is a new prognostic marker in patients with gastric carcinoma
Haese et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer
de Bruin et al. Plasminogen activator profiles in neoplastic tissues of the human colon
Herszényi et al. Proteases in gastrointestinal neoplastic diseases
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
Ramankulov et al. Plasma matrix metalloproteinase‐7 as a metastatic marker and survival predictor in patients with renal cell carcinomas
Strojan et al. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients
Lerner et al. Free, complexed and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate
Sier et al. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Palmieri et al. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay
Wang et al. Benign prostatic hyperplasia‐associated prostate‐specific antigen (BPSA) shows unique immunoreactivity with anti‐PSA monoclonal antibodies
DE60032784D1 (de) Markerproteine für prostatakrebs
Tabarés et al. Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples
Sato et al. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer